Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis

Annals of the New York Academy of Sciences

Volumn 1205, Issue , 2010, Pages 277-283

  Lyritis, George P ^a   Georgoulas, Thomas ^a   Zafeiris, Christos P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

anabolic; anticatabolic; osteoporosis; strontium; teriparatide

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; ESTROGEN DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ANABOLIC AGENT; BONE DENSITY CONSERVATION AGENT; ESTROGEN;

BONE DEVELOPMENT; BONE FRAGILITY; BONE MASS; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; ESTROGEN DEFICIENCY; FEMUR NECK FRACTURE; FRAGILITY FRACTURE; HUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOSYNTHESIS; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR; SPINE FRACTURE; VERTEBRA FRACTURE; BONE; COMPLICATION; DEFICIENCY; DRUG EFFECTS; EVALUATION STUDY; FEMALE; FRACTURES, BONE; METABOLISM; OSTEOPOROSIS, POSTMENOPAUSAL; PHYSIOLOGY;

ANABOLIC AGENTS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; ESTROGENS; FEMALE; FRACTURES, BONE; HUMANS; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 77957063363     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05666.x     Document Type: Conference Paper

References (57)

1. Rosen, C.J. 2003. The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit. Rev. Eukaryot. Gene. Expr. 13: 25-38.
2. Manolagas, S.C. 2000. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21: 115-137.
3. Compston, J.E., S. Vedi, S. Kaptoge & E. Seeman. 2007. Bone remodeling rate and remodeling balance are not coregulated in adulthood: implications for the use of activation frequency as an index of remodeling rate. J. BoneMiner. Res. 22: 1031-1036.
4. Kearns, A.E., S. Khosla & P.J. Kostenuik. 2008. Receptor activator of nuclear factor-B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 29: 155-192.
5. Fonseca, J.E. 2008. Rebalancing bone turnover in favor of formation with strontium ranelate: implications for bone strength. Rheumatology 47: iv17-iv19.
6. Seeman, E.&P.D. Delmas. 2006. Bone quality-thematerial and structural basis of bone strength and fragility. N. Engl. J. Med. 354: 2250-2261.
7. Martin, T.J. & E. Seeman. 2008. Bone remodeling: its local regulation and the emergence of bone fragility. Best Pract. Res. Clin. Endocrinol. Metab. 22: 701-722.
8. Dallas, S.L., J.L. Rosser, G.R.Mundy & L.F. Bonewald. 2002.Proteolysis of latent transforming growth factor-beta (TGFbeta)- binding protein-1 by osteoclasts. A cellular mechanismfor releaseofTGF-beta frombonematrix. J. Biol.Chem. 277: 21352-21360.
9. Ducy, P., M. Amling, S. Takeda, et al. 2000. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197-207.
10. Elefteriou, F., J.D. Ahn, S. Takeda, et al. 2005. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434: 514-520.
11. Aubin, J.E. & J.T. Triffitt. 2002. Mesenchymal stem cells and osteoblast differentiation. In: Principles of Bone Biology. J.P. Bilezikian, L.G. Raisz & G.A. Rodan, Eds.: 59-81. Academic Press. San Diego.
12. Hock, J., L.A. Fitzpatrick & J. Bilezikian. 2002. Actions of PTH. In: Principles of Bone Biology. 2nd ed. Vol.1. J. Bilezikian, L.G. Raisz & G.A. Rodan, Eds.: 463-481. Academic Press. San Diego.
13. Kondo, Y., K. Irie, M. Ikegame, et al. 2001. Role of stromal cells in osteoclast differentiation in bone marrow. J. Bone Miner. Metab. 19: 352-358.
14. Hodge, J.M., M.A. Kirkland & G.C. Nicholson. 2007. Multiple roles of M-CSF in human osteoclastogenesis. J. Cell.Biochem. 102: 759-768.
15. Leibbrandt, A. & J.M. Penninger. 2008. RANK/RANKL: regulators of immune responses and bone physiology. Ann. N. Y. Acad. Sci. 1143: 123-150.
16. Gori, F., L.C. Hofbauer, C.R. Dunstan, et al. 2000. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141: 4768-4776.
17. Takahashi, N., N. Udawawa, M. Takami & T. Suda. 2002. Cells of bone: osteoclast generation. In: Principles of Bone Biology. J.P. Bilezikian, L.G. Raisz & G.A. Rodan, Eds.: 126-198. Academic Press. San Diego.
18. Boyce, B.F. & L. Xing. 2008. Functions of RANKL/RANK/ OPG in bonemodeling and remodeling. Arch. Biochem. Biophys. 473: 139-146.
19. Horowitz, M.C. & J.A. Lorenzo. 2002. Local regulators of bone: IL-1, TNF, lymphotoxin, interferon-γ, IL-8, IL-10, IL- 4, the LIF/IL-6 family, and additional cytokines. In: Principles ofBone Biology. J.P.Bilezikian, L.G. Raisz&G.A.Rodan, Eds.: 961-977. Academic Press. San Diego.
20. Zallone, A. 2006. Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann. N. Y. Acad. Sci. 1068: 173-179.
21. Riggs, B.L. 2000. The mechanisms of estrogen regulation of bone resorption. J. Clin. Invest. 106: 1203-1204.
22. Kostenuik, P.J. 2005. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr.Opin. Pharmacol. 5: 618-625.
23. Riggs, B.L., S. Khosla & L.J. Melton III. 2002. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23: 279-302.
24. Taxel, P., H. Kaneko, S.K. Lee, et al. 2008. Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Osteoporos Int. 19: 193-199.
25. Ammann, P. & R. Rizzoli. 2003. Bone strength and its determinants. Osteoporos Int. 14(Suppl 3): S13-S18. Epub 2003 Mar 19.
26. Duque, G. & B.R. Troen. 2008. Understanding the mechanisms of senile osteoporosis: new facts for a major Geriatric syndrome. J. Am. Geriatr. Soc. 56: 935-941.
27. Seeman E. 2009. Bone modeling and remodeling. Crit. Rev. Eukaryot. Gene. Expr. 19: 219-233.
28. Follin, S.L. & L.B. Hansen. 2003. Current approaches to the prevention and treatment of postmenopausal osteoporosis. Am. J. Health Syst. Pharm. 60: 883-901; quiz 903-4.7.
29. Russell, R.G.G., N.B. Watts, F.H. Ebetino & M.J. Rogers. 2008. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis Int. 19: 733-759.
30. Cummings, S.R., D.M. Black, D.E. Thompson et al. 1998. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077-2082.
31. Harris, S.T., N.B. Watts, H.K. Genant, et al. 1999. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1344-1352.
32. Black, D.M., P.D. Delmas, R. Eastell, et al. 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356: 1809-1822.
33. Chesnut, III C.H., A. Skag, C. Christiansen, et al. 2004. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19: 1241-1249.
34. Blick, S.K., S. Dhillon & S.J. Keam. 2008. Teriparatide: a review of its use in osteoporosis. Drugs 68: 2709-2737. doi: 10.2165/0003495-200868180- 00012.
35. Turner, C.H., D.B. Burr, J.M. Hock, et al. 2001. The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys. Adv. Exp. Med. Biol. 496: 165-179.
36. Kostenuik, P.J., C. Capparelli, S. Morony, et al.; OPG and PTH-(1-34). 2001. Have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 10: 4295-4304.
37. Neer, R.M., C.D.Arnaud, J.R. Zanchetta, et al. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344: 1434-1441.
38. Lewiecki, M.E. 2010. Monitoring pharmacological therapy for osteoporosis.Rev. Endocr.Metab.Disord. 1344-1352/Rev. Endocr. Metab. Disord. Feb 9 [Epub ahead of print].
39. Kamel, H.K.,M.S.Hussain, S. Tariq, et al. 2000. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am. J. Med. 109: 326-328.
40. Kanis, J.A., N. Burlet, C. Cooper, et al. 2008. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 19: 399-428.
41. Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69: 89-95.
42. Bouxsein, M.L. & P.D. Delmas. 2008. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J. Bone Miner. Res. 23: 1155-1167.
43. Gasser, J.A. 2006. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether weare addressing them. Curr. Opin. Pharmacol. 6: 313-318.
44. Bell, K.L., N. Loveridge, J. Reeve, et al. 2001. Super-osteons (remodeling clusters) in the cortex of the femoral shaft: influence of age and gender. Anat Rec. 264: 378-386.
45. Bradbeer, J.N., M.E. Arlot, P.J. Meunier & J. Reeve. 1992. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacingas well as increased thickness of packets of newly formed bone. Clin. Endocrinol. (Oxf). 37: 282-289.
46. Jiang, Y., J.J. Zhao, B.H.Mitlak, et al. 2003. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 18: 1932-1941.
47. Dempster,D.W., F. Cosman, E.S. Kurland, et al. 2001. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. 16: 1846-1853.
48. Oxlund, H.,C.Ejersted,T.T.Andreassen, et al. 1993.Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. Calcif. Tissue Int. 53: 394-399.
49. Uusi-Rasi, K., L.M. Semanick, J.R. Zanchetta, et al. 2005. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36: 948-958.
50. Burr, D.B., T. Hirano, C.H. Turner, et al. 2001. Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J. BoneMiner. Res. 157-165.
51. Meunier, P.J., C. Roux, E. Seeman, et al. 2004. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.N. Engl. J. Med. 350: 459.
52. Reginster, J.Y., E. Seeman, M.C. De Vernejoul, et al. 2005. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis. Treatment of Peripheral Osteoporosis (TROPOS) study. J. ClinEndocrinol. Metab. 90: 2816-2822.
53. Bruyere, O., R. Christian, J. Detilleux, et al. 2007. Relationship between Bonemineral density changes and fracture risk reduction in patients treatedwith strontium ranelate. J. Clin. Endocrinol. Metab. 92: 3076-3081.
54. Reginster, J.-Y., A. Sawicki, Roces-Varela, et al. 2008. 8-years efficacy on vertebral and non-vertebral fractures in postmenopausal osteoporotic women. Osteoporos. Int. 19(Suppl 1): S29-S207.
55. Roux, C. 2008. Strontium ranelate: short- and long-term benefits for postmenopausal women with osteoporosis. Rheumatology 47: iv20-iv22.
56. Reginster, J.Y., D. Felsenberg & S. Boonen. 2008. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebocontrolled trial. Arthritis Rheum 58: 1687-1695.
57. Servier. Protelos. 2009. Available at: . uk/pdfs/Protelos?SPC.pdf. Accessed March 20.